SubscribeLogin
MedCity News image

News from MedCity News

If you want to know if MedCity News is credible or reliable, look no further. We rank MedCity News as Unknown factuality. Find out more about our methodology here.

Information about MedCity News

Where is MedCity News located?MedCity News's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top MedCity News News

Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent - Novo Nordisk (NYSE:NVO)
Europe · Denmark

Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent - Novo Nordisk (NYSE:NVO)

Coverage: 10 sources
Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and operational impacts ahead.See the Story
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA), Sanofi (NASDAQ:SNY)
Business

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA), Sanofi (NASDAQ:SNY)

67% Center coverage: 3 sources
On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of pati…See the Story
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Neurocrine Biosciences (NASDAQ:NBIX)
FDA · San Diego

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Neurocrine Biosciences (NASDAQ:NBIX)

100% Center coverage: 2 sources
On Friday, the FDA approved Neurocrine Biosciences, Inc.(NASDAQ:NBIX) Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). CAH is a rare, inherited disorder that affects the adrenal glands and causes them to be larger than normal. The adrenal glands are locate…See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal